头孢他啶/阿维巴坦
阿维巴坦
肺炎克雷伯菌
头孢他啶
微生物学
孔蛋白
美罗培南
生物
β-内酰胺酶抑制剂
大肠杆菌
医学
抗生素耐药性
抗生素
铜绿假单胞菌
细菌
遗传学
细菌外膜
基因
作者
María Alejandra Mateo-Vargas,Salud Rodríguez-Pallares,Jorge Arca-Suárez,Lorena López‐Cerero,Manuel Rodríguez‐Iglesias,Fátima Galán‐Sánchez
摘要
ABSTRACT De novo infections caused by ceftazidime/avibactam-resistant KPC variants are rarely reported. We characterize the evolution of a KPC-8-producing Klebsiella pneumoniae strain involved in a primary infection without previous ceftazidime/avibactam treatment. During a 15-month follow-up, changes in carbapenem susceptibility due to porin alterations were observed, remaining susceptible to meropenem/vaborbactam, imipenem/relebactam, and cefiderocol. High- and low-permeability recombinant Escherichia coli isolates analysis revealed that, unlike the widespread ceftazidime/avibactam-resistant variant KPC-31, KPC-8 confers ceftazidime/avibactam resistance without decreasing carbapenemase activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI